BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25358384)

  • 1. Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas.
    Gungorduk K; Ozdemir A; Ertas IE; Gokcu M; Telli E; Oge T; Sahbaz A; Sayhan S; Sanci M; Harma M; Ozalp S
    Cancer Res Treat; 2015 Apr; 47(2):282-9. PubMed ID: 25358384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients.
    Tong N; Kumar A; Gelowitz G; Tinker A; Holloway C; Ko J
    Front Oncol; 2023; 13():1035511. PubMed ID: 37091159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis.
    Wong AT; Lee YC; Schwartz D; Lee A; Shao M; Han P; Choi K; Schreiber D
    Int J Gynecol Cancer; 2017 Jul; 27(6):1171-1177. PubMed ID: 28574930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation.
    Makker V; Kravetz SJ; Gallagher J; Orodel OP; Zhou Q; Iasonos A; DeLair D; Aghajanian C; Hensley ML
    Int J Gynecol Cancer; 2013 Nov; 23(9):1635-41. PubMed ID: 24172099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.
    Cicin İ; Özatlı T; Türkmen E; Özturk T; Özçelik M; Çabuk D; Gökdurnalı A; Balvan Ö; Yıldız Y; Şeker M; Özdemir N; Yapar B; Tanrıverdi Ö; Günaydin Y; Menekşe S; Öksüzoğlu B; Aksoy A; Erdogan B; Bekir Hacıoglu M; Arpaci E; Sevinç A
    Balkan Med J; 2016 Sep; 33(5):517-524. PubMed ID: 27761279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma.
    Sozen H; Çiftçi R; Vatansever D; Topuz S; Iyibozkurt AC; Bozbey HU; Yaşa C; Çali H; Yavuz E; Kucucuk S; Aydiner A; Salihoglu Y
    Aust N Z J Obstet Gynaecol; 2016 Apr; 56(2):199-206. PubMed ID: 26890292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy Modalities, Prognostic Factors, and Outcome of the Primary Cervical Carcinosarcoma: Meta-analysis of Extremely Rare Tumor of Cervix.
    Kimyon Comert G; Turkmen O; Karalok A; Basaran D; Bulbul D; Turan T
    Int J Gynecol Cancer; 2017 Nov; 27(9):1957-1969. PubMed ID: 28708788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
    Makker V; Abu-Rustum NR; Alektiar KM; Aghajanian CA; Zhou Q; Iasonos A; Hensley ML
    Gynecol Oncol; 2008 Nov; 111(2):249-54. PubMed ID: 18755503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy and prognosis in uterine carcinosarcoma.
    Chiang CY; Huang HJ; Chang WY; Yang LY; Wu RC; Wang CC; Tung HJ; Chao A; Lai CH
    J Formos Med Assoc; 2021 Nov; 120(11):1977-1987. PubMed ID: 33992491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component?
    Rovirosa A; Ascaso C; Ordi J; Arenas M; Valduvieco I; Lejarcegui JA; Pahisa J; Torne A; Biete A
    Clin Transl Oncol; 2009 Oct; 11(10):681-7. PubMed ID: 19828411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
    Kuku S; Williams M; McCormack M
    Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of adjuvant radiation therapy and prognostic factors in early stage uterine cervical cancer.
    Kim HJ; Rhee WJ; Choi SH; Nam EJ; Kim SW; Kim S; Kim YT; Kim GE; Kim YB
    Radiat Oncol J; 2015 Jun; 33(2):126-33. PubMed ID: 26157682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
    Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
    Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
    van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
    Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
    Zhu J; Wen H; Bi R; Wu X
    J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SATEN III-Splitting Adjuvant Treatment of stage III ENdometrial cancers: an international, multicenter study.
    Kahramanoglu I; Meydanli MM; Taranenka S; Ayhan A; Salman C; Sanci M; Demirkiran F; Ortac F; Haidopoulos D; Sukhin V; Kaidarova D; Stepanyan A; Farazaneh F; Aliyev S; Ulrikh E; Kurdiani D; Yalcin İ; Mavrichev S; Akilli H; Sarı ME; Pletnev A; Aslan K; Bese T; Kairbayev M; Vlachos D; Gultekin M
    Int J Gynecol Cancer; 2019 Oct; 29(8):1271-1279. PubMed ID: 31481453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
    Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
    BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
    Galaal K; van der Heijden E; Godfrey K; Naik R; Kucukmetin A; Bryant A; Das N; Lopes AD
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD006812. PubMed ID: 23450572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.